Shield Therapeutics plc (AIM: STX)
London
· Delayed Price · Currency is GBP · Price in GBX3.300
+0.625 (23.36%)
Nov 21, 2024, 11:51 AM GMT+1
Shield Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 21.47 | 13.09 | 5.5 | 1.52 | 10.39 | 0.72 | Upgrade
|
| Revenue | 21.47 | 13.09 | 5.5 | 1.52 | 10.39 | 0.72 | Upgrade
|
| Revenue Growth (YoY) | 223.99% | 137.95% | 262.01% | -85.38% | 1344.65% | -93.95% | Upgrade
|
| Cost of Revenue | 13.65 | 9.06 | 3.04 | 0.98 | 1.35 | 0.49 | Upgrade
|
| Gross Profit | 7.83 | 4.03 | 2.46 | 0.54 | 9.03 | 0.23 | Upgrade
|
| Selling, General & Admin | 39.71 | 37.96 | 33.65 | 20.15 | 8.61 | 6.77 | Upgrade
|
| Research & Development | 2.13 | 1.81 | 1.32 | 0.79 | 2.58 | 2.5 | Upgrade
|
| Other Operating Expenses | -0.17 | -4.41 | -0.86 | -0.11 | - | - | Upgrade
|
| Operating Expenses | 41.67 | 35.36 | 34.1 | 20.83 | 11.19 | 9.27 | Upgrade
|
| Operating Income | -33.85 | -31.33 | -31.65 | -20.29 | -2.15 | -9.04 | Upgrade
|
| Interest Expense | -2.06 | -1.02 | -0.4 | - | - | -0 | Upgrade
|
| Interest & Investment Income | 0.4 | 0.52 | 0.04 | 0.01 | 0 | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.54 | -0.54 | 0.85 | 0.38 | 0.27 | -0.05 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0 | -0.08 | -0.01 | -0 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -36.06 | -32.38 | -31.24 | -19.91 | -1.89 | -9.07 | Upgrade
|
| Asset Writedown | - | - | -18.11 | - | - | - | Upgrade
|
| Pretax Income | -36.06 | -32.38 | -49.34 | -19.91 | -1.89 | -9.07 | Upgrade
|
| Income Tax Expense | 0.1 | 0.92 | 0.45 | -0.23 | 0.74 | -0.27 | Upgrade
|
| Earnings From Continuing Operations | -36.17 | -33.29 | -49.79 | -19.68 | -2.63 | -8.8 | Upgrade
|
| Net Income | -36.17 | -33.29 | -49.79 | -19.68 | -2.63 | -8.8 | Upgrade
|
| Net Income to Common | -36.17 | -33.29 | -49.79 | -19.68 | -2.63 | -8.8 | Upgrade
|
| Shares Outstanding (Basic) | 762 | 723 | 233 | 204 | 117 | 117 | Upgrade
|
| Shares Outstanding (Diluted) | 762 | 723 | 233 | 204 | 117 | 117 | Upgrade
|
| Shares Change (YoY) | 59.90% | 209.85% | 14.08% | 74.36% | 0.21% | 0.48% | Upgrade
|
| EPS (Basic) | -0.05 | -0.05 | -0.21 | -0.10 | -0.02 | -0.08 | Upgrade
|
| EPS (Diluted) | -0.05 | -0.05 | -0.21 | -0.10 | -0.02 | -0.08 | Upgrade
|
| Free Cash Flow | -20.89 | -37.37 | -22.66 | -18.63 | -1.4 | -4.07 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.05 | -0.10 | -0.09 | -0.01 | -0.03 | Upgrade
|
| Gross Margin | 36.44% | 30.78% | 44.70% | 35.48% | 86.96% | 32.55% | Upgrade
|
| Operating Margin | -157.62% | -239.44% | -575.49% | -1336.01% | -20.74% | -1256.61% | Upgrade
|
| Profit Margin | -168.42% | -254.44% | -905.42% | -1295.46% | -25.32% | -1223.92% | Upgrade
|
| Free Cash Flow Margin | -97.28% | -285.56% | -411.98% | -1226.73% | -13.48% | -565.51% | Upgrade
|
| EBITDA | -33.91 | -31.08 | -29.67 | -18.75 | 0.02 | -6.75 | Upgrade
|
| EBITDA Margin | -157.89% | -237.51% | - | - | 0.23% | - | Upgrade
|
| D&A For EBITDA | -0.06 | 0.25 | 1.97 | 1.54 | 2.18 | 2.29 | Upgrade
|
| EBIT | -33.85 | -31.33 | -31.65 | -20.29 | -2.15 | -9.04 | Upgrade
|
| EBIT Margin | -157.62% | -239.44% | - | - | -20.74% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.